Session » Sjögren's Syndrome – Basic and Clinical Science Poster

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1574

Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum

9:00AM-11:00AM: Abstract Number: 1568

Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1561

B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response

9:00AM-11:00AM: Abstract Number: 1582

Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1570

Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1565

Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1559

Development of Lymphoma in Patients with Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1569

Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter

9:00AM-11:00AM: Abstract Number: 1584

Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina

9:00AM-11:00AM: Abstract Number: 1578

Exercise Increases Aerobic Capacity in Primary Sjögren´s Syndrome: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1586

Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients

9:00AM-11:00AM: Abstract Number: 1556

How Phenotype of the Small Fibre Neuropathy in Primary Sjögren Syndrome Differs from Others Causes of Small Fibre Neuropathy ?

9:00AM-11:00AM: Abstract Number: 1558

Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy

9:00AM-11:00AM: Abstract Number: 1581

Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1562

Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation

9:00AM-11:00AM: Abstract Number: 1583

Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes

9:00AM-11:00AM: Abstract Number: 1587

Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 1580

Persistent Serological Activity in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1566

Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients

9:00AM-11:00AM: Abstract Number: 1585

Primary Sjögren’s Syndrome Stratification Based on the Severity of Patient-Reported Fatigue

9:00AM-11:00AM: Abstract Number: 1563

Risk of Overall Malignancies in Korean Patients with Primary Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 1571

RNA Sequencing Detection of Gene Dysregulation in Epithelial Cells Sorted from Salivary Gland Tissue Reveals Interesting Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology

9:00AM-11:00AM: Abstract Number: 1573

Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus

9:00AM-11:00AM: Abstract Number: 1572

Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome

9:00AM-11:00AM: Abstract Number: 1564

Severe, Life-Threatening Phenotype of Primary Sjögren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry)

9:00AM-11:00AM: Abstract Number: 1579

Sjögren’s Syndrome Is Associated with Reduced Sex Hormone Exposure: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1576

Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1577

Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1575

The Association between Salivary Gland Ultrasonography and Clinical Manifestation in Patients with Early Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1567

The Risk Factors and Prognosis of Interstitial Lung Disease Associated with Primary Sjogren’s Syndrome: A Multi-Center Cohort Study

9:00AM-11:00AM: Abstract Number: 1560

Usefulness of 18F-FDG Positron Emission Tomography for Lymphoma Diagnosis in Patients with Primary Sjögren’S Syndrome

9:00AM-11:00AM: Abstract Number: 1557

Visualization of Dorsal Root Ganglionitis with Three-Tesla Magnetic Resonance Neurography in Sensory Ataxic Neuropathy Associated with Sjögren’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].